The aim of this study was to assess the effect of phosphodiesterase 5 inhibitor, DA-8159, on erectile function throughout the quantitative analysis of vascular endothelial cell, smooth muscle (SM), TGF-b1 expression in rat corpus cavernosum and measurement of intracavernous pressure (ICP) in diabetic rats. DA-8159 (0, 5, 10, 20 mg/kg) was administered orally once a day to diabetic rats. After 8 weeks, immunohistochemistry and computerized image analysis were performed to quantify the percent area within the Corpora Cavernosa occupied by the endothelial cells, SM cells and fibrotic tissues. ICP/mean arterial pressure (MAP) was also measured by electrostimulation of the cavernous nerve. Diabetic rats showed a significant decrease in the SM and endothelial cell content, and an increase in the TGF-b1 expression level within the cavernosa areas compared to the normal rats. The mean cavernous SM, endothelial cell content and TGF-b1 expression level were 9.770.7, 4.570.7 and 17.972.1%, respectively. DA-8159 prevented reduction of SM (12.370.4% (5 mg/kg), 13.870.4% (20 mg/kg)) and endothelial cell content (5.670.5% (5 mg/kg), 6.370.6% (20 mg/kg)). Immunoreactivity of TGF-b1 and intracorporal fibrosis were also significantly lower in DA-8159-treated groups (11.871.2% (5 mg/kg), 9.571.1% (20 mg/kg)). Electrostimulation of the cavernous nerve induced significant increase in maximum ICP (62.2713.6 mmHg in 10 mg/kg vs 37.5717.5 mmHg in diabetic group) and area under the curve of the ratio of ICP/MAP (8891.0971957 in 10 mg/kg vs 6315.8772272 in diabetic group). These results suggest that subchronic treatment of DA-8159 can prevent the development of erectile dysfunction (ED), and provides a rationale for the use of DA-8159 as treatment of diabetic ED.
Introduction
Erectile dysfunction (ED), the consistent or recurrent inability to achieve and maintain an erection adequate for sexual performance, is a common complication of diabetes mellitus. 1 There is a much higher incidence and prevalence of ED in men with diabetes than normal men. As many as 75% of diabetic men will be confronted with ED at some time in their lives, and according to one estimate, 450% of diabetic men will develop ED within 10 y of the onset of diabetes. 2 Although treatment with phosphodiesterase 5 (PDE5) inhibitors is less effective in diabetic patients than in nondiabetic ED patients, recent trials have demonstrated that oral PDE5 inhibitors are effective and well tolerated in men with concomitant ED and diabetes. [3] [4] [5] DA-8159 is a potent PDE5 inhibitor developed by the Dong-A Pharmaceutical Company to treat ED. In previous studies, it was shown that DA-8159 induces a penile erection in various animal models and relaxed the corpus cavernosal smooth muscle (SM) from diabetic rabbits. 6, 7 On the other hand, recent research continues to investigate the efficacy and potential applications of PDE5 inhibitors in other disorders where SM dilation is involved. 8, 9 The application of PDE5 inhibitors to treat cystic fibrosis, 10 gastroparesis, 11 pulmonary hypertension 12 and congestive heart failure 13 is currently under investigation. Moreover, a PDE5 inhibitor has been shown to enhance the endothelium-dependent vasodilation and improve the endothelial dysfunction. 14 Sildenafil, which was the first PDE5 inhibitor used to treat ED, preserves intracorporal SM content and abrogates the development of the intracorporal fibrosis in human. 15 In addition, Sildenafil significantly increases the intracorporal endothelial cell and SM content when administered in combination with free oxygen radical scavengers. 16 Leungwattanakij et al 17 demonstrate an increase in transforming growth factor (TGF)-b1, hypoxia inducible factor (HIF)-1a and collagen III synthesis in rat cavernosal smooth musculature after cavernous neurotomy, and suggested that cavernous fibrosis may be reduced by using various vasoactive agents or interventions that increase the oxygenation to the corporal tissues. Therefore, we hypothesized that DA-8159 can prevent and reverse cavernosal dysfunction by preserving intracorporal SM and endothelial cell content, and also attenuate the development of intracorporal fibrosis, which eventually results in improvement of erectile function.
Histologically, ED is associated with a diffuse reduction in the cavernosal SM and endothelial cell content, and an increase in the connective tissue elements, particularly in men with diabetes. 18 Similar histological changes were observed in the cavernosum of hypercholesterolemic rabbits and streptozotocin (STZ)-induced diabetic rats. 19, 20 They reported that the SM and endothelial cell density is significantly lower in the corpora cavernosa (CCs) of diabetic rats. Therefore, in order to investigate the above hypothesis, we assessed the effect of DA-8159 on the contents of endothelial and SM cells in the CCs of the STZ-induced diabetic rats, and additionally investigated the effect DA-8159 on intracavernous pressure (ICP) using an in vivo model.
Materials and methods

Test materials
DA-8159 ( Figure 1 ) is a pyrazolopyrimidinone derivative with a molecular weight of 516.66, which was synthesized by the Dong-A Pharmaceutical Company (Youngin, Korea). DA-8159 was dissolved in a Titrisol s buffer solution (citrate sodium hydroxide buffer, pH 5.0, Merck) for oral administration. STZ was purchased from Sigma Chemical Co. (USA). All the reagents used in immunohistochemistry for SM cell, endothelial cell and TGF-b1 expression were purchased from Abcam (Cambridge, UK), BD Bioscience (NJ, USA) and Santa Cruz Biotechnology (California, USA), respectively. All other chemicals or reagents were commercial and of the highest quality available.
Animals
This study was performed in accordance with the institutional 'Standard procedure for animal care and experiments' of the Dong-A Pharmaceutical Co Ltd, and with the 'Guide for the Care and Use of Laboratory Animals' from the National Institutes of Health. Sprague-Dawley (SD) rats, 8-week old, were randomized into four groups containing at least 12 rats. Group 1 animals (n ¼ 20) were injected intravenously with saline and served as a normal control. Group 2-4 animals were induced to become diabetic by a single intravenous injection of STZ (55 mg/kg/ 1 ml). These rats were tested at 1 week after inducing hyperglycemia using a glucose test kit (ONE TOUCH BASIC, Lifescan, USA), and animals with a blood glucose level of 300 mg/dl or more were used. After confirming the onset of diabetes, the animals were divided into three groups, one STZ control (n ¼ 20) and two treatment groups (each n ¼ 12). DA-8159 was orally administered once a day for 8 weeks in a dose of 5 or 20 mg/kg. All the rats were killed by a lethal overdose of sodium pentobarbital (100 mg/ kg, i.p.) at week 8 to obtain the penile tissues. The penile tissues were obtained via a circular incision made at the corona with the subsequent removal of the foreskin and shaft skin, and amputation of the penis at the most extreme proximal position possible. Excess blood was removed by gently blotting the penis on a sterile cotton gauze, and specimens for immunohistochemical analysis were flash frozen in liquid nitrogen and stored at À701C until sectioning. Half of the penises from each group were fixed in formalin, dehydrated, embedded in paraffin and sectioned for either immunohistochemistry or Masson's trichrome staining as described previously. PDE5 inhibition and erectile function GJ Ahn et al
Immunohistochemistry
The standard ABC staining kits (ab8642, abcam) were applied to perform immunohistochemistry of a-actin to detect the SM cells. 16, 20 Briefly, the penile sections from the formalin-fixed, paraffin-embedded samples were deparaffinized, and hydrated in a graded series of ethanol solutions with a decreasing concentration. Then, an endogenous enzyme blocker was applied to inactivate the endogenous peroxide. After rinsing with PBS, a tissue conditioner was applied for 5 min and slides were treated with 1% bovine serum albumin (BSA) in 1 Â PBS to inhibit hydrophobic interaction. Mouse monoclonal antibodies to a-actin (ab7817-500, abcam) were diluted to 1:50 in 1% BSA in 1 Â PBS and incubated for 30 min at room temperature. The negative controls for immunohistochemistry were not given the primary antibodies. Biotinylated secondary antibodies and anti-mouse/rat IgG were added to the sections for an incubation period of 30 min. After rinsing, two to four drops of avidin phosphatase reagent were added to the sections and incubated for 20 min. A working Fast red chromogen was applied and incubated for 10 min at room temperature and sections were counterstained with hematoxylin.
For CD-31 immunostaining to detect endothelial cells, 16, 20 penile shafts obtained at exsanguination of animals were treated with pre-cooled isopentane and frozen in a compound medium. Transverse sections of 6 mm thickness were cut on a cryostat at À251C and transferred onto microslides, which were air-dried for 30 min at room temperature and incubated in cold acetone at À201C for 15 min. After washing in 1 Â PBS, the endogenous enzyme blocker was applied to the frozen sections to inactivate the endogenous peroxide, employing the same method described above using the standard ABC staining kits (ab8642, abcam). The primary antibodies, and biotinylated anti-rat CD-31 antibodies (PECAM-1, BD bioscience), were diluted to 1:100 in 10% mouse serum in 1 Â PBS and applied to the sections for 30 min at room temperature. The AP reagent and working chromogen reagent (Fast red chromogen) were applied and sections were counterstained with hematoxylin.
Immunohistochemistry to identify TGF-b1 expression was modified according to several methods. 22, 23 Immunoperoxidase procedure kit (Santa Cruz Biotechnology, USA) was applied in this study. Sections, 4 mm thick, were placed onto the slides, deparaffinized and hydrated, and were treated with 3% H 2 O 2 in methanol for 30 min to inactivate the endogenous peroxidase. After washing in PBS, the sections were blocked in PBS containing 1.5% normal goat serum for 1 h. The sections were then incubated with the primary antibodies, and the TGF-b1 antibodies (1:200; Santa Cruz Biotechnology) for 12-14 h at 41C. After removing the unbound primary antibodies and rinsing with PBS, the sections were incubated with biotin-conjugated secondary antibodies (1:200; Santa Cruz Biotechnology) for 1 h at room temperature and then incubated with avidin-biotinylated horseradish peroxidase (Vectastain Elite ABC kit; Vector Laboratories) for 30 min, followed by diaminobenzidine (DAB) treatment.
Computerized image analysis
The volumetric densities of the SM cells, endothelial cells and fibrotic tissues, which are the relative volumes these structures occupy in the tissue, were determined using the color analysis software. All the analyses were performed with a microscope (Zeiss, Germany) connected to a digitalized camera (Cool SANP, USA), which transferred the captured image to a microcomputer. From each animal, five randomly selected sections stained with either antia SM actin, anti-CD31 or TGF-b1 were used, and five fields per slide, totaling 25 fields per animal, were obtained. The photomicrographs were taken from these fields, scanned and quantified for the area occupied by Fast red (red) stained SM or endothelial cells, and peroxidase (brown) immunostained TGFb1 expression using a computerized image analysis system, Imaga-Pro s Plus (Media Cybernetics, USA). Image analysis calculated the percentage of the stained areas relative to the total cellular area. The total cellular area on the photomicrograph was corrected for the luminal areas of the vascular spaces and other noncellular areas.
Measurement of ICP
For this measurement, DA-8159 10 mg/kg was administered orally once a day for 8 weeks to diabetic rats (n ¼ 10). Animals were anesthetized with sodium pentobarbital (50 mg/kg, i.p.). The penile skin was incised and the prepuce was degloved to completely expose the CC. A 26-gauge needle connected to a polyethylene (PE) tube and filled with physiological saline containing 50 IU/ml heparin was inserted into the CC on one side to measure the ICP. The carotid artery was cannulated to continuously monitor the mean arterial pressure (MAP). These parameters were recorded on a polygraph and the data acquisition and calculation of the derived parameters were performed using an on-line computer system (Signal processor, USA). Major pelvic ganglion and pelvic and cavernous nerves were exposed through a midline abdominal incision. A stainless steel bipolar electrode was carefully positioned around the cavernous nerve. Stimulation was performed at 10 Hz for 60 s with a pulse duration of 5 ms and 3 V using a stimulator (Electrical Stimulator, HSE, USA). The stimulus PDE5 inhibition and erectile function GJ Ahn et al interval was 10 min. These conditions were obtained from the preliminary study to determine the optimal stimulatory conditions. The maximum ICP (mmHg), the ratio of ICP/MAP and the area under the curve (AUC) of the ratio of ICP/MAP were measured.
Statistical analysis
The data were analyzed Mann-Whitney U-test using SigmaStat s for Windows 2.0 software (Jandel corporation, USA), and compared by an analysis of variance (ANOVA) on the square root of the arcsine of the percentage area of the endothelial and SM cells and the TGF-b1 expression level in each group. The ICP data are expressed as the mean7s.e.m., and body weight changes and blood glucose levels are expressed as the mean7s.d. Any differences among the treatment groups were evaluated by ANOVA, followed by the Dunnett test for a post hoc comparison of the means against the control. A P-value o0.05 was considered significant.
Results
General characteristics of diabetic rats Table 1 shows the general characteristics of the STZinduced diabetic rats. The diabetic rats demonstrated a significant loss in the total body weight relative to the normal controls. The DA-8159 treatment, which was initiated 1 week after inducing diabetes, did not significantly affect the total body weight and the serum glucose levels.
Immunohistochemical localization of SM cells
The presence of SM cell in penile CC was investigated by immunohistochemistry with anti-SM a-actin monoclonal antibodies. The results showed that the SM cells had a discrete localization in the trabeculae, forming a narrow subendothelial layer that surrounds the lumina of the CC, and were found in small clusters representing the small vascular elements in both normal and diabetic controls (Figure 2) . Interestingly, morphometric analysis of the sections showed a significant reduction in the density in diabetic animals (Po0.05). Cavernosal area occupied by the SM cells was 15.170.4% in the normal control and 9.770.7% in the diabetic control group, respectively (Table 2 ). In the case of the treatment group, although both 5 and 20 mg/kg treatment significantly increased the SM cell contents (12.370.4 and 13.870.4%) when compared to diabetic control (Po0.05), 5 mg/kg treatment represented a significant difference compared to normal control (Po0.05). These results corresponded to the identification of the SM cells in the rat penile CCs by Masson's trichrome staining (Figure 4 ).
Immunohistochemical localization of endothelial cells
In order to identify the endothelial cells, anti-CD31 antibodies were used to stain the sections from these PDE5 inhibition and erectile function GJ Ahn et al same rats. Similar to the staining of the anti-SM a-actin, small clusters of brown staining endothelial cells were found at the periphery of the tissues lining the sinusoidal spaces. These sections were also analyzed using the quantitative computerized image analysis system to assess the area occupied by the brown staining endothelial cells of the corpora.
The results in Table 2 show that the endothelial cell content of the cavernosum was approximately 7.470.7% in the normal control group, but was reduced significantly to 4.570.7% in the diabetic groups (Po0.05). Interestingly, DA-8159 20 mg/kg treatment showed a significant increase of endothelial cell content (6.370.6%) when compared to diabetic control (Po0.05), but there was a tendency to increase in the 5 mg/kg treatment group (5.670.5%).
Immunohistochemical localization of TGF-b1 expression
Immunostaining of the penile sections with anti-TGF-b1 antibodies clearly revealed the distribution of TGF-b1 expression in the CC. The immunoreactivity of TGF-b1 in the diabetic group was prominent in subepithelial regions such as collagen connective tissue, fibroblasts and SM fibers ( Figures  3, 4) . The localization of TGF-b1 in CC was supported by the immunostaining experiments using the anti-a-actin antibodies and Masson's trichrome staining (Figure 4 ). The staining pattern was almost identical to that observed for a-actin and trichrome staining. Although the immunoreactivity for TGF-b1 in the diabetic control group was significantly higher than that in the normal control group (17.972.1 vs 3.470.6%, Po0.05), DA-8159 treatment significantly reduced the immunoreactivity both in the 5 mg/kg (11.871.2, Po0.05) and 20 mg/kg groups (9.571.1, Po0.05) compared to diabetic control ( Figure 3 and Table 2 ).
ICP
Cavernosal nerve electrical stimulation caused an increase in the ICP/MAP ratio both in normal and diabetic control rats. In diabetic control rats, the baseline cavernous pressure ranged from 5.58 to 6.12 mmHg (mean 5.9170.22, n ¼ 10), which was significantly lower than that in the normal rats (mean 11.9470.45, Po0.05). The maximum ICP was also significantly lower in the diabetic control group (37.5717.5 mmHg) than in the normal group (67.1710.1 mmHg; Figure 5 ). In contrast, the rats treated with the subchronic administration of DA-8159 showed a maximum ICP value of 62.2713.6 mmHg, which produced significant increase compared to diabetic control (Po0.05) and was comparable to that of the normal control ( Figure 5 ). Figure 6a describes the time-course changes of ICP/MAP ratio (%), and the data expressed as AUC of ICP/MAP ratio were significantly increased from 6315.8772272 (diabetic group) to 8891.0971957 (DA-8159 10 mg/kg) (Figure 6b ).
Discussion
The CC consists of SM cells, loose areolar tissues, blood vessels, nerves and collagen fibers, which is PDE5 inhibition and erectile function GJ Ahn et al essential for a penile erection and is implicated with ED. In particular, SM cells play a critical role in corporal relaxation, and the reduction in their number or a dysfunction can lead to an ED. 24, 25 The importance of the SM has been appreciated in both animal experiments and human clinical studies, and alterations occurring in the structure of the different components in DM have been reported. 20, 26 Recently, it was reported that image analysis of the CCs in the STZ rat model is a reliable and reproducible research tool for assessing the diabetes-related vascular damage. 20 Therefore, we examined the penile tissues from rats to determine whether diabetes may quantitatively affect the SM content, the endothelial cell density and the TGF-b1 expression level in the CCs consistent with the loss of the erectile function, and also investigated whether the changes were attenuated by the subchronic administration of the PDE5 inhibitor, DA-8159.
Previous studies on erectile function in the STZinduced diabetic rats have shown that this condition adversely affects the erectile capability, with a reduction in the ICP responses to nerve stimulation after only 2-3 months following the STZ treatment. 27 However, in this study, the result showed that an 8-week period of the STZ-induced diabetes caused a measurable and significant reduction in the SM cell and endothelial cell content, as well as an increase in TGF-b1 expression in the CCs concomitant with a loss of erectile function. The mean area of the cavernosum occupied by SM cells was PDE5 inhibition and erectile function GJ Ahn et al reduced from approximately 15% in the control group to approximately 10% in the diabetic group. In addition, the mean area of the endothelial cells was reduced from 7.4% in the control group to 4.5% in the diabetic group. This supports the fact that diabetes induces quantitative vascular damage in rat erectile tissue after an 8-week period, and was comparable to those of the previous results. 20, 28 The subchronic administration of DA-8159 attenuated the development of these changes in a dosedependent manner. There was a significant difference between the SM and endothelial cell content of the CCs in the DA-8159-treated groups compared to the diabetic control. The mean area of the cavernosum occupied by SM and endothelial cells was approximately 13% (12.3% in 5 mg/kg and 13.8% in 20 mg/kg of DA-8159) and 6% (5.6% in 5 mg/kg and 6.3% in 20 mg/kg of DA-8159), respectively. These results suggest that DA-8159 prevents the loss of SM and endothelial cells, and may have a beneficial effect on the pathological changes secondary to diabetes induced by STZ.
Undoubtedly, SM cells play critical roles in erectile function and dysfunction. However, the end product of the degeneration of SM cells is collagen fiber deposition. An increase in the intracavernous collagen fibers means a more severe corporal fibrosis, which may affect corporeal relaxation. Therefore, the content of the collagen fibers in the CC may be another parameter to use in diagnosing erectile function. 29 TGF-b1 is a cytokine that induces connective tissue synthesis and inhibits the growth of vascular SM cells; the two principal changes observed in corporal fibrosis. 18, 25, [30] [31] [32] Indeed, TGF-b1 treatment shows a dose-dependent decrease in the percentage of corporal SM and induces the fibrosis in situ by altering the level of connective tissue synthesis. 33, 34 In this study, we used an image analysis system to objectively quantify the collagen fiber content in the CC by examining the TGF-b1 expression level. In diabetic rats, the TGF-b1 expression level was increased significantly with a mean area of 17.9% compared to the control rats (3.470.6%). The localization of TGF-b1 expression in CC corresponded with the identification of the Masson's trichrome staining. However, in both groups treated with DA-8159, the immunoreactivity of TGF-b1 was reduced, suggesting that the level of intracorporal fibrosis was significantly decreased by subchronic DA-8159 treatment.
In the rat model, ICP measurements have gained wide acceptance for evaluating erectile function because of the similarities between humans and rats with respect to erections. 35 In this study, the ICP of diabetic and DA-8159-treated rats was measured to assess the effect of DA-8159 on erectile function. At 8 weeks after the STZ injection, the maximum ICP and the ICP to BP ratio of diabetic rats were significantly lower than in the control rats. These results were comparable to the previous study, which demonstrates that diabetic rats consistently showed lower ICP increases in response to physical manipulation, pharmacological stimulation and electrostimulation of cavernous nerve. 27 However, in contrast, the decrease in the ICP was significantly recovered by the DA-8159 treatment. These results clearly showed that the subchronic administration of DA-8159 preserved the erectile response to electrical nerve stimulation in the diabetic rats.
In summary, this study found that experimental diabetes was accompanied by a decrease in the SM and endothelial cell content, and the associated TGF-b1 overexpression, eventually resulting in a decrease in the ICP. These changes were all ameliorated by the subchronic treatment with the PDE5 inhibitor, DA-8159. These results suggest that the subchronic treatment of DA-8159 can partially prevent the development of ED experimentally induced by STZ administration, providing a rationale for the potential use of DA-8159 for treating ED secondary to diabetes mellitus.
